Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - |
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Rocket Pharmaceuticals Inc | RCKTW | NASDAQ | Equity Warrant |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.07 | 08:30:01 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.07 |
| Trades | Shares Traded | Average Volume |
|---|---|---|
| 0 | 0 | - |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | 0.07 | USD |
Rocket Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 6.31M | 90.16M | - | 0 | -245.6M | -2.72 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
News Rocket Pharmaceuticals
| Date | Time | Source | Heading |
|---|---|---|---|
| 6/10/2024 | 09:34 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of.. |
| 5/20/2024 | 15:36 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/20/2024 | 15:33 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/20/2024 | 15:29 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/20/2024 | 15:26 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 5/16/2024 | 15:27 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 5/16/2024 | 14:44 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 5/16/2024 | 14:41 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 5/16/2024 | 14:41 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities |
| 5/06/2024 | 16:26 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
RCKTW Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. |
